Research Paper Volume 12, Issue 24 pp 25101—25119
Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker
Figure 3. Mutational landscape of genes involved in pathways of microtubule inhibitors (MTIs) in TCGA-STAD cohort. (A) Protein-protein interaction (PPI) network of genes that significantly enriched in microtubule inhibitors (MTIs) representative gene sets. (B) Mutational landscape of node genes from PPI network showing that CENPF, KIF26B, and DYNC1H1 were highly mutated in TCGA-STAD cohort (alteration frequency ≥ 7%) by the GenVisR package. Top for somatic mutation rate of each sample, bottom left for the total mutation frequency of each gene, and bottom right for specific mutation type of each gene in each sample.